Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL AND ASPIRIN versus OZOBAX DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL AND ASPIRIN versus OZOBAX DS.
CARISOPRODOL AND ASPIRIN vs OZOBAX DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.
None Documented
None Documented
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Terminal elimination half-life is 1.0-1.5 hours in patients with normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
Renal: 70-80% unchanged; fecal: 20-30%; biliary: <5%
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant